"Analyst valuations
Following the positive Phase 3 trial results in December, the analysts covering Neuren significantly increased their current risk-adjusted valuations, with the range now $5.05 to $7.70 per share. In addition, Neuren was selected by Bioshares as one of the “Top 6 Picks for 2022” and was added to its model portfolio."
Ann: Q4 2021 quarterly activity and cash flow report, page-2
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |